Progress and strategy for axillary management of breast cancer
10.3760/cma.j.cn115396-20220301-00064
- VernacularTitle:乳腺癌腋窝处理进展及策略
- Author:
Chaobin WANG
1
;
Fuzhong TONG
Author Information
1. 北京大学人民医院乳腺中心，北京 100044
- Keywords:
Breast neoplasms;
Sentinel lymph node biopsy;
Axillary dissection;
Lymph nodes
- From:
International Journal of Surgery
2022;49(3):145-150
- CountryChina
- Language:Chinese
-
Abstract:
With the understanding of the biological characteristics of breast cancer and the improvement of systemic treatment, the treatment concept of breast cancer has changed, and the treatment strategy of axillary lymph nodes has also been constantly changing. With the change of these concepts, a large number of relevant clinical trials have been gradually carried out. The NSABP B04 study took the lead in exploring the transformation of axillary treatment strategies in the classic breast cancer treatment. Although this study did not change the clinical practice of axillary treatment at the time, it provided a preliminary data basis for a subsequent series of clinical studies on axillary preservation. In these changes, sentinel lymph node biopsy, as a milestone in the surgical treatment of breast cancer, has become the standard staging procedure for axillary negative patients. Since then, a series of related clinical studies have also been carried out, among which the results of studies on patients with low-load axillary metastasis have confirmed the feasibility of axillary preservation in some patients, which has influenced and changed clinical practice. In addition, the results of the study make it possible for some patients to preserve the axilla after neoadjuvant therapy reduce postoperative upper extremity edema effectively. Whether axillary surgery can be completely eliminated, and whether axillary dissection can be waived for patients with positive axilla after neoadjuvant therapy under the premise of equal survival benefit have also received extensive attention.
